ProPhase Labs, Inc. Q2 FY2024 earnings call

Pharmaloz

• Seasonality: Pharmaloz is seasonal due to cold lozenge demand, but now attracting year-round brands to address this. Plans to expand beyond seasonal business.
• Strategic alternatives: Pursuing strategic alternatives for Pharmaloz with ThinkEquity, aiming for a large liquidity event in Q1 next year.

Nebula Genomics

• Rebranding: Undergoing rebranding with new social media strategies and products, including DNA Expand to enhance ancestry test reporting.
• Lab utilization: Converted COVID lab to genomics lab, aiming to fill it with Nebula Genomics business.

BE-Smart Esophageal Cancer test

• Consultant collaboration: Working with FHC consultants to navigate FDA, insurance, and physician networks. Has strong board connections to physician networks.

Equivir

• Study results: Over 300 patients in final stages of study with phenomenal results in prophylactic and therapeutic arms, targeting retail interest.

Pharmaloz

• Revenue: Estimated $14 million to $16 million in revenues and $5 million plus in profits over next 12 months. Operates at capacity. Seasonal but now attracting year-round lozenge brands to address seasonality.
• Revenue contribution: Significant, with plans to expand beyond seasonal business.

Nebula Genomics

• Revamped go-to-market strategy, hired social media experts (Stuart Hollenshead) to enhance marketing. Has world-class whole genome sequencing product and lab but needs business to support lab. Developing DNA Expand product to expand ancestry test reporting.
• Revenue contribution: Small currently, but expected to ramp up with rebranding and social media efforts.

BE-Smart Esophageal Cancer test

• Working with FHC consultants to commercialize. Faces FDA and insurance challenges but targets a large market (7 million endoscopies annually). Potential multibillion dollar market.

Pharmaloz

• Expectations: Estimated $14M-$16M revenues and $5M+ profits over next 12 months, with potential for line two and beyond to increase these numbers.
• Timing: Potential large liquidity event for Pharmaloz in Q1 next year.

Nebula Genomics

• Launch: Upcoming rebranding and social media launches within weeks, with expectations of ramping up business.

Risks

• Regulatory: Uncertainty in obtaining and maintaining regulatory approvals for BE-Smart and Nebula products.
• Economic: Impact of general economic conditions on consumer demand for products.
• Seasonality: Continued seasonality challenges for Pharmaloz despite efforts to address it.
• Competition: Intense competition in the lozenge, genomics, and cancer testing markets.

Q: Please provide some detail about Forward Healthcare and why you choose them.

A: The three consultants have different skill sets covering FDA, physician networks, and tying it all together, working closely with ProPhase to commercialize BE-Smart. They aim to build a multibillion dollar market for the test.

Q: My family has a history of esophageal cancer. When can I obtain the BE-Smart test?

A: It's complicated due to FDA and insurance challenges. Can provide the test as a cash-based option, but commercialization involves CPT codes and insurance reimbursement, with no definite timeline yet.

Q: Please elaborate on your recent SEC filing about the CrowdStrike incident preventing ProPhase from filing its Q2 results on time. Is this an ongoing issue for the company?

A: No ongoing issue. Results were reported four days later, which is allowed, and there's no current issue related to CrowdStrike.

Q: Does ProPhase continue to have an investment in Lantern Pharma? And if so, what is the thinking about it? Long-term hold or potential source of cash in the short term? And if Pharmaloz is generating cash and growing, why look to sell this one profitable asset?

A: Refused to comment on Lantern Pharma, stating it's a question related to Lantern rather than ProPhase's current call.

Q: What is happening at the diagnostics lab if there's no more COVID testing?

A: Converted COVID lab to genomics lab for Nebula Genomics, aiming to fill it with DNA Complete business, with potential to sell the lab in the future.

Q: It looks like there are now only two options for Nebula, Deep and Ultra Deep. Did you discontinue the standard option, and what was the rationale? Are you no longer offering lifetime memberships?

A: Rebranding and new products will clarify this soon, with new websites and rebranding launching shortly, and details to be provided in coming weeks.

Q: When will the second line at the factory become operational, and is potential production spoken for?

A: Second line expected to install this year, with negotiations ongoing for production. Tradeoffs between large customers (lower margins but stable) and small customers (higher margins but more work).

Q: Can you please discuss the marketing approach for BE-Smart if approved? Would you anticipate further partnerships to assist?

A: Potential partnerships with large cancer diagnostic companies or leveraging physician network connections, with options including IPOs or spinouts for value realization.

Q: Please address the adequacy of your liquidity until revenues ramp up.

A: Money flowing in regularly, with Pharmaloz contributing this quarter, and expected cash from strategic alternatives, though no definitive timeline, but ample cash currently.

Q: How far are we from having the family doctor request a DNA genomics test along with regular blood tests on a patient to determine if there is a risk of disease?

A: Personalized precision medicine is the future, with initiatives like testing couples before marriage and babies, and services like matchmaking potentially incorporating genomics tests.

Q: Looks like the second half of 2024 could bring several major milestone events. Will you be able to stay on top of all initiatives?

A: Has strong teams in each department, with experts running Nebula Genomics and BE-Smart, and a strong finance team, so not solely dependent on one person, but has a motivated team to handle initiatives.